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prevalence and spatial distribution of malaria 
in Ethiopia
Ashenafi Assefa1,2* , Ahmed Ali Ahmed2, Wakgari Deressa2, Heven Sime1, Hussein Mohammed1, 
Amha Kebede3, Hiwot Solomon4, Hiwot Teka5, Kevin Gurrala6, Brian Matei6, Brian Wakeman6, G. Glenn Wilson7, 
Ipsita Sinha8,9, Richard J. Maude8,9,10, Ruth Ashton11, Jackie Cook12, Ya Ping Shi6, Chris Drakeley12, 
Lorenz von Seidlein8,9, Eric Rogier6 and Jimee Hwang13
Abstract 
Background: Measures of malaria burden using microscopy and rapid diagnostic tests (RDTs) in cross-sectional 
household surveys may incompletely describe the burden of malaria in low-transmission settings. This study 
describes the pattern of malaria transmission in Ethiopia using serological antibody estimates derived from a nation-
wide household survey completed in 2015.
Methods: Dried blood spot (DBS) samples were collected during the Ethiopian Malaria Indicator Survey in 2015 from 
malarious areas across Ethiopia. Samples were analysed using bead-based multiplex assays for IgG antibodies for six 
Plasmodium antigens: four human malaria species-specific merozoite surface protein-1 19kD antigens (MSP-1) and 
Apical Membrane Antigen-1 (AMA-1) for Plasmodium falciparum and Plasmodium vivax. Seroprevalence was estimated 
by age, elevation and region. The seroconversion rate was estimated using a reversible catalytic model fitted with 
maximum likelihood methods.
Results: Of the 10,278 DBS samples available, 93.6% (9622/10,278) had valid serological results. The mean age 
of participants was 15.8 years and 53.3% were female. National seroprevalence for antibodies to P. falciparum was 
32.1% (95% confidence interval (CI) 29.8–34.4) and 25.0% (95% CI 22.7–27.3) to P. vivax. Estimated seroprevalences for 
Plasmodium malariae and Plasmodium ovale were 8.6% (95% CI 7.6–9.7) and 3.1% (95% CI 2.5–3.8), respectively. For 
P. falciparum seroprevalence estimates were significantly higher at lower elevations (< 2000 m) compared to higher 
(2000–2500 m) (aOR 4.4; p < 0.01). Among regions, P. falciparum seroprevalence ranged from 11.0% (95% CI 8.8–13.7) 
in Somali to 65.0% (95% CI 58.0–71.4) in Gambela Region and for P. vivax from 4.0% (95% CI 2.6–6.2) in Somali to 36.7% 
(95% CI 30.0–44.1) in Amhara Region. Models fitted to measure seroconversion rates showed variation nationally and 
by elevation, region, antigen type, and within species.
Conclusion: Using multiplex serology assays, this study explored the cumulative malaria burden and regional 
dynamics of the four human malarias in Ethiopia. High malaria burden was observed in the northwest compared 
to the east. High transmission in the Gambela and Benishangul-Gumuz Regions and the neglected presence of P. 
malariae and P. ovale may require programmatic attention. The use of a multiplex assay for antibody detection in low 
transmission settings has the potential to act as a more sensitive biomarker.
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Background
Malaria transmission in Ethiopia is non-stable, het-
erogeneous and seasonal, with peak periods following 
the main rains from June to September and short rains 
from March to April [1]. Historically, malaria epidemics 
occurred at 5 to 8-year intervals. The last malaria epi-
demic in 2004/2005 caused two million clinical cases and 
claimed approximately 3000 lives [2, 3]. Although malaria 
transmission has been declining over the past 15 years [4, 
5], 60% of the Ethiopian landmass is suitable for malaria 
transmission and communities remain vulnerable for 
malaria transmission. The National Malaria Control Pro-
gramme of Ethiopia considers areas below 2000 m eleva-
tion as malaria endemic and eligible for malaria control 
activities [6]. Plasmodium falciparum and Plasmodium 
vivax are the major documented malaria parasite spe-
cies, with approximately 1.2 million P. falciparum cases 
and 678,000 P. vivax cases reported in 2015 [7]. The pro-
portion of P. vivax cases has been increasing whereas a 
decline in P. falciparum incidence was observed [8].
With the decline in malaria cases, measuring malaria 
transmission intensity and dynamics is becoming 
increasingly challenging. Transmission estimates using 
standard malaria diagnostic tests, such as microscopy or 
rapid diagnostic tests (RDT), entomological inoculation 
rate, and splenomegaly prevalence fail to detect changes 
in the malaria burden in very low transmission settings 
[9]. The last three Ethiopian Malaria Indicator Surveys 
(EMIS) reported very low prevalence, using microscopy 
and RDTs: 0.9% by microscopy in 2007, 1.3% by micros-
copy and 4.5% by RDTs in 2011, and 0.5% by microscopy 
and 1.2% by RDT in 2015 [10–12]. With decreasing para-
site prevalence as well as density of individual infections, 
the sensitivity of conventional diagnostic tools has been 
declining [13, 14]. Serological and molecular epidemio-
logical studies may be more useful in such scenarios, and 
are being increasingly used for measuring malaria bur-
den in low transmission settings [15–17]. Robust sero-
prevalence estimates of Plasmodium infections could be 
critical for monitoring and evaluation of ongoing malaria 
control and elimination activities in Ethiopia.
In this study, multiplex serological methods were used 
to estimate malaria exposure, transmission patterns, and 
spatial and regional distribution of malaria in Ethiopia, 
using samples collected during the 2015 EMIS.
Methods
Study area
The study was conducted as part of the National Ethio-
pian Malaria Indicator Survey in 2015 (EMIS-2015). 
Ethiopia has successfully implemented three national 
EMISs in 2007, 2011 and 2015 [10–12]. EMIS-2015 
was embarked during the peak of malaria transmission 
season, between September and December 2015. The 
sampling design provided national and sub-national esti-
mates of major malaria intervention indicators, including 
malaria prevalence for malarious areas of the country, as 
well as estimates for areas below 2000 m elevation, areas 
between 2000 and 2500  m, and for 10 administrative 
regions.
Study design and sample collection
EMIS-2015 was a cross-sectional survey that used a 
two-stage cluster sampling approach. A total of 555 enu-
meration areas (EAs) were selected proportional to the 
population size of the regions, as estimated by the Ethio-
pian Central Statistics Agency. In each EA, 25 households 
were randomly selected following onsite EA household 
mapping. A total of 53,335 individuals were surveyed in 
13,875 selected households. Demographic, socio-eco-
nomic, use of malaria prevention, and malariometric data 
were collected in the selected households from each EA. 
Children under 5 years of age in each selected house-
hold and persons of all ages in every fourth household 
were eligible for biological sample testing. Whole blood 
from a finger prick from consenting individuals was col-
lected for a malaria RDT (histidine‐rich protein 2 (HRP2) 
and Plasmodium lactate dehydrogenase (pLDH) antigen 
 CareStart®, AccessBio, US), a malaria blood slide (thick 
and thin blood film), haemoglobin (Hemocue Hb 201+ , 
Hemocue AB, Ängelholm, Sweden) measurement, and 
dried blood spot (DBS) samples. Whatman 903 Protein 
Saver (GE Healthcare, Pittsburgh, PA, USA) filter paper 
was used for DBS collection. Filter papers were air dried, 
individually packed in a plastic bag together with a desic-
cant and stored at − 20 °C at the Ethiopian Public Health 
Institute (EPHI) before they were shipped for further lab-
oratory-based testing at the US Centers for Disease Con-
trol and Prevention (CDC), Atlanta, GA, USA.
Ethical consideration
The EMIS-2015 protocol received ethical clearance from 
the National Research Ethics Review Committee of Ethi-
opia and PATH. The survey protocol underwent human 
subjects review at CDC and was considered to be a non-
research programme evaluation activity. Additional ethi-
cal clearance for the present serology study was obtained 
from the Institutional Review Board of the College of 
Health Sciences of the Addis Ababa, University (AAUMF 
03-008).
Blood spot elution, bead coupling and antigens used 
in the study
Laboratory analysis was conducted as previously 
described [15]. Briefly, a 6-mm punch was used from each 
DBS sample and blood eluted to a 1:20 concentration 
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in blocking buffer (Buffer B: Phosphate Buffered Saline 
(PBS) containing 0.5% Bovine Serum Albumin (BSA), 
0.05% Tween 20, 0.02% sodium azide, 0.5% polyvinyl 
alcohol, 0.8% polyvinylpyrrolidone and 0.5% w/v Escheri-
chia coli extract) overnight.
Six Plasmodium antigens were used for this study: 
two P. falciparum antigens (Merozoite Surface Protein-1 
19kD (MSP-1) and Apical Merozoite Antigen-1 (AMA-
1), two P. vivax antigens (PvMSP-1 and PvAMA-1), one 
P. malariae (PmMSP-1) and one P. ovale (PoMSP-1). The 
four Plasmodium MSP-1 19kD antigens were produced 
as recombinant proteins and purified as described previ-
ously [18]. The external domain of P. falciparum AMA-1 
antigen was produced at the Walter Reed Army Institute 
of Research (WRAIR) under previously published con-
ditions [19]. The P. vivax AMA-1 antigen was produced 
at the London School of Hygiene and Tropical Medicine 
(LSHTM) under previously published conditions [20]. 
The Schistosoma japonicum glutathione-S-transferase 
antigen (GST) was produced recombinantly and served 
as a generic protein to assess immunoglobulin G (IgG) 
non-specific binding.
All antigens were coupled to magnetic beads (Luminex 
Corp, Austin, TX, USA) as per prior studies [18, 21]. 
Briefly, beads were pulse vortexed, transferred to a 
microcentrifuge tube and centrifuged for 1.5  min at 
13,000g. Supernatant was removed, and the beads were 
washed with a 0.1 M and pH 6.2 sodium phosphate (NaP) 
solution. Beads were activated by suspending in NaP with 
5  mg/mL of EDC (1-ethyl-3-[3-dimethylaminutesopro-
pyl] carbodiimide hydrochloride) and 5  mg/mL sulfo-
NHS (sulfo N-hydroxylsulfosuccinimide) and incubating 
with rotation for 20 min at room temperature (RT), while 
protected from light. After a wash with coupling buffer 
(50  mM 2-(4-morpholino)-ethane sulfonic acid, 0.85% 
NaCl at pH 5.0), antigens were coupled to beads in the 
presence of a coupling buffer for 2 h at a concentration 
of 20 ug/mL for all antigens, except for PvAMA1 and 
GST at 15 ug/mL. Beads were washed once with PBS and 
suspended in PBS with 1% bovine serum albumin (BSA) 
with incubation for 30 min at RT by rotation. Beads were 
then resuspended in a storage buffer (PBS, 1% BSA, 0.02% 
sodium azide and 0.05% Tween-20) and stored at 4  °C. 
Coupled beads were run with a panel of known malaria 
seronegatives to assure minimal non-specific MFI signal 
would be given by beads used in this study.
The DBS elution was assayed for IgG antibodies using 
bead-based multiplex technology, and all wash steps were 
performed with a handheld magnet. In 5 mL of reagent 
buffer (Buffer A: PBS, 0.5% BSA, 0.05% Tween-20, 0.02% 
 NaN3), a bead mix was prepared with all coupled bead 
regions included (approximately 625 beads/antigen per 
well), and 50 uL bead mix was pipetted into each well of 
a BioPlex Pro plate (BioRad, Hercules, CA, USA). Beads 
were washed twice with 100 µL PBS with Tween (PBST), 
and 50  µL of the reagent mix [in 5  mL Buffer A: 1:500 
anti-human IgG (Southen Biotech), 1:625 anti-human 
 IgG4 (Southern Biotech), 1:200 streptavidin-PE (Invitro-
gen)] was added to each well. Negative control samples 
and a dilution curve of hyperimmune serum were added 
to each assay plate to monitor any change in control val-
ues over the course of the study. Samples of blood eluted 
from DBS were added to predefined wells (already con-
taining beads and reagent mix) at 1:50 dilution. Plates 
were incubated overnight with gentle shaking at RT and 
protected from light. The next morning (approximately 
16  h total incubation time), plates were washed three 
times, and beads were re-suspended with 100 µL PBS and 
read on a MAGPIX machine (Luminex Corp, Austin, TX, 
USA). Mean fluorescence intensity (MFI) signal was gen-
erated for a minimum of 50 beads/region, and the back-
ground (bg) MFI from wells incubated with Buffer B was 
subtracted from each sample to give a final value of MFI-
bg. Minimal variation was seen in the assay signal for the 
background or positive hyperimmune serum curve val-
ues, so no plates were re-run for the study.
Statistical analysis
Data analysis was done using Stata 13 software (College 
Station, USA). Samples with GST MFI-bg reads above 
1000 MFI value (non-specific binding) were excluded 
from the analysis (n = 678). To dichotomize seropositiv-
ity,  log10-transformed MFI-bg values were fitted to a two-
component Finite Mixture Model (FMM) by the FMM 
procedure with normal distribution and maximum like-
lihood estimation outputs. A seropositivity cutoff value 
was determined by the mean MFI-bg value of the first 
(assumed seronegative) component plus three standard 
deviations [18]. Overall, P. falciparum and P. vivax sero-
positivity were defined as an individual being positive 
for either or both of the MSP-1 and AMA-1 antigens 
for each species. Seropositivity estimates for P. malariae 
and P. ovale are presented using the seropositivity cut-off 
method outlined above. However, to minimize cross-
reactivity between the species-specific MSP-1 antigens, 
the current study report an additional conservative two-
stage approach that increase specificity, but decrease 
sensitivity of the specific antibodies to the targeted anti-
gens. For this conservative approach for P. malariae and 
P. ovale, individual readings for PmMSP-1 or PoMSP-1 
response first had to be above the MFI-bg cutoff as 
described above. Additionally, the PmMSP-1 and/or 
PoMSP-1 MFI-bg signal for that sample also needed to 
be above the PfMSP-1 MFI-bg signal for the same sam-
ple (ratio to PfMSP-1 greater than 1.0) to be considered 
PmMSP-1 and/or PoMSP-1 positive.
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A reversible catalytic model was fitted to the dichot-
omized data using maximum likelihood methods to 
generate a seroconversion rate (SCR or λ) and a seror-
eversion rate (ρ). The model was used to generate age 
seroprevalence curves, from which a seroconversion 
rate (SCR) representing the force of infection for the 
community was calculated. Evidence for two forces of 
infection was investigated, if visual inspection of SCR 
curves indicated such a comparison and was guided by 
a profile likelihood plots to determine the most likely 
time (year) of change in transmission [16, 22]. Multiple 
logistic regression models were employed to determine 
odds ratios (OR); 95% confidence intervals (CI) for gen-
der, age and elevations. Similar regression models were 
employed for P. falciparum and P. vivax seropositivity. 
Adjustments were made by region, elevation and age 
group.
Empirical bayesian kriging in ArcGIS version 10.5 
(ESRI, CA, USA) was used to predict the spatial dis-
tribution of seroprevalence as a continuous surface of 
probability of being above a cut-off. This is an estab-
lished method that uses a statistical model to predict 
and interpolate the spatial distribution of a variable 
from available data [23]. Maps were developed sepa-
rately for MSP-1 and AMA-1 antigens for both P. falci-
parum and P. vivax for all individuals and for children 
under 5 years of age. Seroprevalence by woreda/district 
was compared with the 2015 annual parasite incidence 
(API) data. QGIS version 2.1.8 and ArcGIS version 10.5 
(ESRI, Redlands, CA) were used to produce maps.
Sampling weights calculated during MIS 2015 were 
used to ensure the representativeness of the samples 
tested to the study population.
Results
Study population
Of the expected 15,829 DBS samples, 10,278 individual 
DBSs were available for the current study, serological 
results were generated for 93.6% (9622/10,278) of these 
(Fig.  1). A total of 8944 results were merged with the 
EMIS-2015 data base, of which 52.3% (95% CI (50.8–
53.7)) of the survey participants were female (Table  1). 
Figure 2 shows the spatial distribution of EAs providing 
serology data. The overall proportion of samples col-
lected from children under 5  years was 44.8% (95% CI 
43.0–46.5); although this proportion was above 60% in 
the Afar and Somali Regions (Table  1). The number of 
individuals with serology data within an EA ranged from 
1 to 55, with a mean of 24 individuals per EA. Over-
all mean age was 15.8  years (95% CI 15.2–16.4) (range 
1–107). Of the samples collected, 75.0% (95% CI 67.5–
81.2) were from areas with elevation less than 2000 m.  
A total of 0.8% (95% CI 0.6–1.2) of the participants 
were positive by RDT; comprising 0.5% (95% CI 0.3–0.7) 
for P. falciparum (HRP2 antigen positive), 0.2% (95% CI 
0.1–0.4) for either P. vivax, P. malariae or P. ovale (Pv/
Pm/Po) (pan-LDH antigen positive), and 0.1% (95% CI 
0.1–0.3) considered as a mixed infection (HRP2 and 
pan-LDH positive). More than 90% of the positive P. 
falciparum RDT results were from the Gambela and 
Fig. 1 Flow chart showing sample selection and analysis procedure
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Benishangual-Gumuz Regions. 62.1% (95% CI 57.5–66.6) 
of respondents said they used a bed net during the previ-
ous night (Table 1).
Seroprevalence
Nationally, 32.1% (95% CI 29.8–34.4) of the participants 
were seropositive for any IgG against the two P. falci-
parum antigens, and 25.0% (95% CI 22.7–27.34) for P. 
vivax. Only 6.6% (95% CI 5.5–8.0) of participants were 
seropositive for both P. falciparum and P. vivax, while 
41.1% (95% CI 38.5–43.7) of individuals were positive 
either for P. falciparum or P. vivax. Eight point six per-
cent (95% CI 7.6–9.7) and 3.1% (95% CI 2.5–3.8) were 
seropositive for P. malariae and P. ovale, respectively 
(Table  2). By antigen, 23.8% (95% CI 21.4–26.3) were 
positive against P. falciparum MSP-1 and 24.5% (95% 
CI 22.4–26.7) AMA-1, while for P. vivax, 21.2% (95% CI 
19.2–23.4) were positive against MSP-1 and 14.4% (95% 
CI 12.7–16.2) AMA-1.
For children under 5 years of age, 18.0% (95% CI 16.1–
20.1) and 14.8% (95% CI 12.7–17.2) were seropositive for 
P. falciparum and P. vivax, respectively. Similarly, 33.3% 
(95% CI 30.4–36.2) of male children were seropositive for 
P. falciparum compared to 30.9% (95% CI 28.3–33.6) of 
the females [aOR: 1.3 (95% CI 1.1–1.4), p < 0.05] (Addi-
tional file  1). A similar trend was observed for P. vivax, 
where 26.4% (95% CI 23.4–29.7) of males compared to 
23.6% (95% CI 21.1–26.3) of females were seropositive 
[aOR: 1.3 (95% CI 1.1–1.5), p > 0.05].
Seroprevalence by age
The DBS sample collection was purposely biased towards 
children under 5 years of age, with 44.8% (95% CI 43.0–
46.5) of the DBS samples having been collected from this 
age group. Seropositivity increased with age group. This 
pattern was more pronounced for P. falciparum than P. 
vivax, although the difference was significant in both 
Plasmodium species (p < 0.05).
Conservative estimate for Plasmodium malariae 
and Plasmodium ovale
Table  3 shows of all samples tested, 5.1% (95% CI 4.4–
6.0) were seropositive for P. malariae and 1.5% (95% CI 
1.1–2.0) for P. ovale using the conservative approach 
to define seropositivity. Both species were observed in 
all the regions, albeit with a variable distribution. The 
Fig. 2 Distribution of dried blood spot (DBS) samples collected from selected malaria endemic areas of Ethiopia as part of the national, 
cross-sectional, household Malaria Indicator Survey conducted in 2015 (EMIS-2015). Each point depicts a cluster of sampled households in an EA. 
Shading indicates elevation which ranges from − 131 m below sea level (lightest) to 4092 m (darkest)
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proportion of seropositives was slightly lower for both 
species, accordingly to the conservative estimation 
method. A similar trend of seropositivity was observed 
for children under 5 years of age (Table 3).
Seroprevalence by region
The proportion of individuals seropositive was variable 
by region, with P. falciparum seropositivity higher than P. 
vivax seropositivity in all the regions (Fig. 3). The propor-
tion seropositive for P. falciparum by region ranged from 
11.0% (95% CI: 8.8–13.7) in Somali to 65.0% (95% CI: 
58.0–71.4) in Gambela Region and for P. vivax from 4.0% 
(95% CI: 2.6–6.2) in Somali to 36.7% (95% CI: 30.0–44.1) 
in Amhara Region.
The API data from 2014 (API 2014) obtained from the 
Federal Ministry of Health (Additional file  2), observed 
high malaria transmission in Gambela, Benishangul-
Gumuz and Amhara Regions. By antigen comparison, P. 
falciparum API showed greater association with PfMSP-1 
[Rho of 0.37 and p < 0.01 (spearman correlation)] and P. 
vivax API with PvAMA-1 (Rho 0.32 and p < 0.01).
Seroprevalence by elevation
Seropositivity was inversely related to elevation for P. fal-
ciparum, with lower elevation (< 2000  m) areas having 
significantly higher seroprevalence compared to areas of 
higher elevation (2000–2500 m) [aOR 4.36 (95% CI 2.7–
7.0), p < 0.01]. The highest seropositivity was observed 
for P. falciparum at elevations below 1500 m and a peak 
was observed at an elevation below 1000  m (Fig.  4a). A 
weaker inverse effect of elevation was observed for P. 
vivax. There was no significant difference in the trans-
mission of P. vivax between above and below 2000 m (OR 
1.5 (95% CI 0.9–2.4), p > 0.05). Among children under 
Table 2 Proportion of individuals (all ages and under 5 years) found to be malaria seropositive by species and by antigen 
in malaria endemic areas of Ethiopia, 2015
Samples positive for Merozoite Surface Protein-1 (MSP-1) and/or Apical Membrane Antigen-1 (AMA-1) for the respective species were considered positive for that 
species
Pf, Plasmodium falciparum; Pm, Plasmodium malariae; Po, Plasmodium ovale; Pv, Plasmodium vivax
a Normal approach (mean seronegative +3sd) to defining cut-off level used for P. malariae and P. ovale
Plasmodium species Antigens % seropositive (95% CI) (all 
ages)
% seropositive 
(95% CI) (under 
5 years)
P. falciparum MSP-1 23.8 (21.4–26.3) 12.3 (10.6–14.2)
AMA-1 24.5 (22.4–26.7) 11.3 (9.8–13.0)
Pf positive (MSP-1 and/or AMA-1) 32.1 (29.8–34.4) 18.0 (16.1–20.1)
P. vivax MSP-1 21.2 (19.2–23.4) 12.3 (10.5–14.4)
AMA-1 14.4 (12.7–16.2) 6.7 (5.5–8.0)
Pv positive (MSP-1 and/or AMA-1) 25.0 (22.7–27.3) 14.8 (12.7–17.2)
P. malariaea MSP-1 8.6 (7.6–9.7) 6.1 (5.0–7.3)
P. ovalea MSP-1 3.1 (2.5–3.8) 2.0 (1.4–2.7)
Any Plasmodium Pf (MSP-1/AMA-1) or Pv (MSP-1/AMA-1) or Pm MSP-1 
or Po MSP-1
44.5 (41.9–47.2) 30.2 (27.3–33.2)
Either P. falciparum or P. vivax Pf (MSP-1/AMA-1) or Pv (MSP-1/AMA-1) 41.1 (38.5–43.7) 26.7 (24.0–29.5)
Both P. falciparum and P. vivax Pf (MSP-1/AMA-1) and Pv (MSP-1/AMA-1) 6.6 (5.5–8.0) 1.7 (1.2–2.4)
Table 3 Proportion seropositive for less common malarias 
[P. malariae Merozoite Surface Protein-1 (PmMSP-1) and P. 
ovale Merozoite Surface Protein-1 (PoMSP-1)], using 
the conservative approach to defining seropositive cut-off 
values, by region and age group, in malaria endemic areas 
of Ethiopia, 2015
Pm, Plasmodium malariae; Po, Plasmodium ovale
Region All ages Under 5 years
PmMSP-1 PoMSP-1 PmMSP-1 PoMSP-1
Tigray 1.1 (0.6–2.3) 0.6 (0.3–1.1) 1.1 (0.4–2.9) 0.3 (0.1–1.2)
Afar 1.3 (0.6–3.0) 0.6 (0.1–2.7) 1.8 (0.7–4.2) 0.5 (0.1–4.2)
Amhara 5.0 (3.2–7.6) 2.4 (1.8–3.3) 2.7 (1.1–6.2) 1.0 (0.3–3.1)
Oromia 6.3 (5.0–7.8) 2.0 (1.3–3.0) 5.8 (4.4–7.8) 1.8 (1.0–3.3)
Somali 1.3 (0.6–2.8) 0.1 (0.0–0.8) 1.1 (0.4–2.9) 0
Benishangul-
Gumuz
2.1 (1.0–4.4) 0.7 (0.2–2.5) 1.3 (0.4–4.7) 1.5 (0.4–4.9)
Southern 
Nation and 
Nationalities 
People’s
4.9 (3.7–6.3) 0.6 (0.4–1.2) 4.7 (3.1–7.1) 0.7 (0.3–1.8)
Gambela 0.2 (0.1–1.1) 0.1 (0.0–0.5) 0.3 (0.1–1.2) 0
Harari 4.5 (0.6–26.4) 4.0 (0.3–33.6) 0 0
Dire Dawa 2.4 (0.7–8.0) 0.8 (0.1–5.3) 1.7 (0.3–9.9) 0
Total (%) 5.1 (4.4–6.0) 1.5 (1.1–2.0) 4.6 (3.6–5.7) 1.2 (0.8–1.9)
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5 years of age, P. falciparum and P. vivax both showed a 
significant although varying relationship with elevation. 
Plasmodium vivax showed direct relation with increasing 
elevation. High P. vivax seropositivity was observed at 
higher elevations above 1500 m (Fig. 4b). No significant 
effect of elevation on seropositivity was detected for the 
rare species, P. malariae and P. ovale (p > 0.05).
Generally, seropositivity was found to vary in space, 
with elevation and among administrative regions, as 
depicted in Fig. 5. An interpolated surface map predicted 
differing transmission patterns for P. falciparum and P. 
vivax. Higher seropositivity is predicted in the northwest 
compared to the southeast.
Seroconversion curves
The overall age seroconversion plot for antibody 
responses for both P. falciparum and P. vivax are shown 
in Fig.  6. In general, higher seroconversion rates were 
observed for P. falciparum compared to P. vivax both for 
the combined MSP-1/AMA-1 outcome and individual 
MSP-1 and AMA-1 antigens; and MSP-1 antigen show 
higher seroconversion rates compared to AMA-1 anti-
gens for both species. Heterogeneity was observed across 
the different antigen responses. A similar trend was 
observed when the model was fitted to data with eleva-
tion below 2000  m and combined MSP-1 and AMA-1 
antigens. Regionally, the seroconversion model was fitted 
to the four major administrative regions (Amhara, Oro-
mia, SNNP, Tigray) both for P. falciparum and P. vivax 
MSP-1 and AMA-1 antigen responses. Heterogeneous 
seroconversion rates were observed over the regions 
(Additional files 3 and 4). For seroconversion plots, 
where visual inspection indicated better fit between the 
observed and predicted pattern of transmission, two 
forces of infection were compared with a single force 
of infection. This showed a non-significant change over 
around two decades for both P. falciparum and P. vivax 
antigen responses (p > 0.05).
Fig. 3 Mean seropositivity by region for Plasmodium falciparum and Plasmodium vivax, 2015. An individual was considered positive if they had a 
positive antibody response either for Merozoite Surface Protein-1 (MSP-1) or Apical Membrane Antigen-1 (AMA-1) antigens for each species. a All 
ages; b children under 5 years of age. Error bars indicate the 95% confidence interval (BG: Benishangul-Gumuz and SNNPR: Southern Nations and 
Nationalities People’s Region)
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Discussion
The current study documented malaria seroprevalence 
in Ethiopia using samples collected from a national 
EMIS conducted in 2015. Of all samples analysed, 
32.1% had IgG antibodies against combined P. falcipa-
rum MSP-1 or AMA-1 antigens, and 25.0% for P. vivax 
MSP-1 or AMA-1. The relative numbers were lower for 
children under 5 years of age at 18.0% for P. falciparum 
and 14.8% for P. vivax, suggesting a lower recent trans-
mission in Ethiopia. Seropositivity in children under 
5 years of age may accurately represent recent infection 
as they have had limited exposure and time to gener-
ate the cumulative antibody response seen in adults 
[24–26]. The serological results were cumulative anti-
body responses for the relatively long-term markers of 
transmission, MSP-1 and AMA-1 antigens [16, 22, 27–
29]. The RDT results for the study samples showed 0.8% 
positivity for Plasmodium, of which 0.5% was due to P. 
falciparum.
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Fig. 4 Mean seropositivity for Plasmodium falciparum Merozoite Surface Protien-1 (MSP-1) or Apical membrane Antigen-1 (AMA-1), and 
Plasmodium vivax MSP-1 or AMA-1 by elevation category, 2015. An individual was considered positive if they had a positive antibody response 
either for Merozoite Surface Protien-1 (MSP-1) or Apical Membrane Antigen-1 (AMA-1) antigens for each species. Broken line depicts P. falciparum 
(MSP-1/AMA-1) and solid line represent P. vivax (MSP-1/AMA-1). a All ages; b children under 5 years of age. Error bars indicate the 95% confidence 
interval
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Generally, significantly higher levels of P. falciparum 
transmission were observed in areas of lower elevation 
(< 2000  m). This is consistent with previous studies [1, 
17, 19], and attributed to the ambient temperature and 
moisture requirements of the Anopheles vector mos-
quitoes [30]. This reaffirms the national malaria con-
trol programme’s strategy in which high elevation areas 
(> 2000  m) are considered to be areas where malaria is 
not transmitted and thus not targeted for vector control 
but only case management interventions. However, the 
evidence of increasing P. vivax seropositivity with eleva-
tion over the range of the study setting could expand 
the understanding of malaria transmission in Ethiopia. 
The relapse of P. vivax infections may have contributed 
to the high P. vivax prevalence observed at higher eleva-
tions [31–35]. Travel history is reported to be a risk fac-
tor for malaria exposure in Ethiopia [24–26], but in the 
EMIS-2015 only 2% reported travel history a month prior 
to the survey [12].
Seropositivity was high for children under 5  years of 
age, particularly in the Gambela and Benishangul Gumuz 
Regions, although was lower than in adults. These show 
higher malaria transmission that may need a more inten-
sive approach for malaria control in the affected areas. A 
larger proportion of males than females were seropositive 
for both P. falciparum and P. vivax. Increased malaria risk 
in men in Ethiopia has been attributed to a greater extent 
of outdoor, occupational exposure [24–27, 36].
A total of 8.6% of individuals were seropositive for P. 
malariae and 3.1% for P. ovale. Variable trends of pro-
portion seropositive were observed in the regions for 
both species. These findings, albeit with high proportion, 
support previous reports of sporadic occurrence of P. 
malariae and P. ovale that may be responsible for up to 
Fig. 5 An interpolated surface map for Plasmodium falciparum antigen responses [a Apical Membrane Antigen-1 (AMA-1) and b Merozoite 
Surface Protein-1 (MSP-1)] and Plasmodium vivax antigen responses (a AMA-1 and b MSP-1). Darker colour shows high probability of being above 
the cut-off for seropositivity and lighter colour lower. Empirical bayesian kriging was used to produce the maps from serology data from samples 
collected during Ethiopian Malaria Indicator Survey (EMIS 2015)
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1% of the malaria incident cases in Ethiopia [30, 37–40]. 
Currently there is no reporting system for these Plasmo-
dium species, P. malariae and P. ovale, in Ethiopia. Anti-
body cross-binding among the different MSP-1 antigens 
has been documented as non-substantial [18, 41]. In 
the present study, data was analysed using an additional 
conservative approach to defining seropositivity to rule 
out the possibility of IgG cross-binding, thus reporting 
the most conservative estimates for comparison. Using 
this approach would potentially increase specificity but 
decrease sensitivity. The overall seropositivity, although 
reduced, was 5.1% for P. malariae and 1.5% for P. ovale, 
with the regional trend and pattern of transmission 
remaining similar.
The use of serological methods in measuring malaria 
transmission in low-transmission settings has been 
documented in a number of studies [15, 16, 27, 36, 42, 
43]. Application of serology methods was suggested for 
Ethiopia because of the very low prevalence of malaria 
through RDT and microscopy methods across several 
national surveys [27, 36, 42]. The estimate was too low to 
track progress over the years or give detailed information 
Fig. 6 National age-seroconversion plots for antibody responses for Plasmodium falciparum and Plasmodium vivax antigens [Merozoite Surface 
Protien-1 (MSP-1) and Apical Membrane Antigen-1 (AMA-1)]. Y-axis represents probability of being seropositive and the X-axis age. Seroconversion 
curves represent the rate at which a population becomes seropositive to specific antigens resulting in seroconversion rates (SCR) or lambda (λ). In 
each graph points represent age seroprevalence (by deciles), unbroken line represents maximum likelihood curves and broken lines represent the 
95% confidence interval. a and d depict the seroconversion rates for combined (MSP-1/AMA-1) P. falciparum antigen response (a) and for combined 
(MSP-1/AMA-1) P. vivax antigen response (d). Plots b and c show seroconversion rates for individual P. falciparum antigens MSP-1 (b) and AMA-1 (c). 
Plots e and f show seroconversion rates for individual P. vivax antigens MSP-1 (e) and AMA-1 (f)
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about differences in malaria burden by region or risks 
of infection due to demographic or behavioural fac-
tors. By describing exposure to malaria over a longer 
period, serology data were able to better document dif-
ferences in exposure between age groups, regions and by 
elevation.
The findings show the magnitude of transmission 
intensity was highly variable among different regions 
and elevations in Ethiopia. Yalew et al. reported similar 
trends with 30.0 and 21.8% seroprevalence for P. falcipa-
rum and P. vivax, respectively, for the Amhara region in 
2013 [36]. The current study reported 32.1% for P. falci-
parum and 25.0% for P. vivax for the same region. The 
slight variation in seropositivity may be attributed to the 
different type of laboratory assay used. The challenge of 
comparing data from ELISA and bead-based multiplex 
serology has been investigated previously [15]. Results 
from multiplex serology were more robust, sensitive 
and ideal for large-scale surveys compared to ELISA 
[15]. Heterogeneity of response for the different anti-
gens was demonstrated in several studies. Ashton et al. 
[27] described MSP-1 antigens to be better biomark-
ers for P. falciparum, although Cook et al. [16] reported 
AMA-1 to be better for measuring P. falciparum in 
low-transmission settings. Characterization of antigen 
markers may be required to further qualify the serol-
ogy methods [44]. The current finding was in agreement 
with the API data from 2014 obtained through routine 
surveillance. Although routine surveillance can provide 
crucially important data for decision making for coun-
tries at lower transmission, additional biomarkers to 
track malaria burden can serve as ancillary data as sur-
veillance systems continue to improve and dynamically 
evolve in completeness and quality.
The study had several limitations. Only 65% of DBS 
samples from the EMIS-2015 survey were available for 
serological analysis. Although no systematic bias was 
introduced and frequencies were weighted, the repre-
sentativeness of this sample at the national and regional 
levels should be interpreted cautiously. The data were 
insufficient to produce refined spatial heat maps and the 
maps produced show only general trends. Samples col-
lected are assumed to reflect the malaria exposure of 
their respective locations and did not account for poten-
tial population movement. Although the survey reported 
very low recent travel history, past travel encompassing 
the previous harvest season as well as previous years 
were not captured and could reflect past malaria expo-
sure risk from a different locale. This study assessed 
long-term markers of transmission, but further char-
acterizing antigens based on local eco-epidemiology is 
recommended to identify and select specific short- and 
long-term markers.
Conclusion
The current study explored the malaria burden and 
transmission intensity using serological markers of 
exposure to four malaria species. It documented the 
magnitude, spatial distribution and dynamics of trans-
mission over differing elevation, administrative regions, 
and age groups using samples collected during a national 
programme evaluation survey with minimal sample 
preparation time and cost. These findings confirmed the 
National Malaria Control Programme data of the rela-
tive high transmission in the Gambela and Benishangul-
Gumuz Regions and highlighted gaps in the current 
understanding of malaria epidemiology. The increase of 
P. vivax seropositivity with elevation and the presence 
of P. malariae and P. ovale in all administrative regions 
(given P. ovale requires hypnozoiticidal treatment) may 
require programmatic consideration in selecting diag-
nostic tools and appropriate treatment guidelines. These 
results can be used as baseline data to evaluate the 
recent malaria elimination efforts in Ethiopia especially 
as routine surveillance systems are progressively being 
strengthened.
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Additional file 1. Percent malaria seropositivity and Odds Ratio (OR) 
by sex, age and elevation for each species in malaria endemic areas of 
Ethiopia, 2014.
Additional file 2. An Interpolated surface map for P. falciparum (left) and 
P. vivax (right). Empirical bayesian kriging was used to produce the maps 
from the Annual Parasite Incidence data in Ethiopia (API 2014).
Additional file 3. Regional age-seroconversion plots for antibody 
responses for Plasmodium falciparum antigens. Y-axis represents prob-
ability of being seropositive and the X-axis age. Seroconversion curves 
represent the rate at which a population become seropositive to specific 
antigens resulting in seroconversion rates (SCR) or lambda (λ). In each 
graph points represent age seroprevalence (by deciles), unbroken line rep-
resents maximum likelihood curves and broken lines represent the 95% 
confidence interval. Plots A and B depict the seroconversion curves for 
P. falciparum antigens response to MSP-1 (A) and AMA-1(B) for the major 
four regions Tigray, Amhara, Oromia and Southern Nations and Nationali-
ties People’s Regions.
Additional file 4. Regional age-seroconversion plots for antibody 
responses for P. falciparum antigens. Y-axis represents probability of being 
seropositive and the X-axis age. Seroconversion curves represent the rate 
at which a population become seropositive to specific antigens resulting 
in seroconversion rates (SCR) or lambda (λ). In each graph points represent 
age seroprevalence (by deciles), unbroken line represents maximum likeli-
hood curves and broken lines represent the 95% confidence interval. Plots 
A and B depict the seroconversion curves for P. vivax antigens response 
to MSP-1 (A) and AMA-1 (B) for the major four regions, Tigray, Amhara, 
Oromia and Southern Nations and Nationalities People’s Region (SNNPR).
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